Investigational drug · Phase 3
ONO-4578
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "ONO-4578"
First trial start
2024
Jan 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ONO-4578", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Esophagogastric Junction Cancer
- Esophageal Adenocarcinoma
- Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ONO-4578" as an intervention, largest first.
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaPivotal-lookingNot yet recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07818070 · 600 participants (planned) · Start Feb 2027 · Primary completion Jan 2031
Drug: ONO-4578; Nivolumab and 6 more · For: Gastric Cancer; Esophagogastric Junction Cancer; Esophageal Adenocarcinoma
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Pivotal-lookingActive, not recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT06256328 · 226 participants · Start Jan 10, 2024 · Primary completion Oct 9, 2025
Drug: ONO-4578; Oxaliplatin and 4 more · For: Gastric Cancer
Sites: Nagoya, Japan; Kashiwa-shi, Japan; Matsuyama, Japan · 63 sites in all
- Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsActive, not recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT03155061 · 183 participants (planned) · Start Apr 19, 2017 · Primary completion Mar 2028
Drug: ONO-4578; ONO-4538 · For: Advanced or Metastatic Solid Tumors
Sites: Nagoya, Japan; Toyoake, Japan; Kashiwa, Japan · 22 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT06948448 · 144 participants (planned) · Start Nov 18, 2025 · Primary completion Feb 15, 2028
Drug: ONO-4578; Opdivo® and 4 more · For: Colorectal Cancer
Sites: Phoenix, Arizona; Los Angeles, California; Lone Tree, Colorado · 39 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT06538207 · 46 participants · Start Jan 13, 2021 · Primary completion Oct 1, 2024
Drug: ONO-4578; ONO-4538 and 6 more · For: Metastatic Pancreatic Cancer
Sites: Kashiwa-shi, Japan; Yokohama, Japan; Hamamatsu, Japan · 9 sites in all
- ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT06570031 · 46 participants · Start Nov 9, 2021 · Primary completion Apr 30, 2026
Drug: ONO-4578; letrozole and 2 more · For: Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer and 1 more
Sites: Nagoya, Japan; Chiba, Japan; Kashiwa-shi, Japan · 13 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT06542731 · 42 participants · Start Jun 1, 2021 · Primary completion Oct 30, 2025
Drug: ONO-4578; ONO-4538 and 2 more · For: Non-small Cell Lung Cancer
Sites: Shinden, Japan; Chuo Ku, Japan; Bunkyō City, Japan · 13 sites in all
- Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerActive, not recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT06547385 · 40 participants · Start Jan 13, 2021 · Primary completion Oct 31, 2027
Drug: ONO-4578; ONO-4538 and 5 more · For: Colorectal Cancer
Sites: Kashiwa-shi, Japan; Kobe, Japan; Yokohama, Japan · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Cancer-Associated Fibroblasts and Prostaglandin E2 Signaling in Gastric Cancer: Immunometabolic Mechanisms and Implications for Immunotherapy Resistance.
Xu C, Wang Y, Zhang Q, et al. · Int J Mol Sci 2026
- EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Nakayama I, Ryu MH, Lim SH, et al. · J Clin Oncol 2026
- ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Kawazoe A, Yamaguchi K, Hamaguchi T, et al. · Cancer Sci 2025
- First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors.
Iwasa S, Koyama T, Nishino M, et al. · Cancer Sci 2023
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.